MFC Co

MFC Co Equity

The The Equity of MFC Co (432980.KQ) as of Oct 29, 2026 is 28.33 B KRW. In the previous year, The Equity was 17.74 B KRW — a change of 59.69% (higher).

Equity

28.33 BKRW

YoY

59.69%

Last updated:

In 2024, MFC Co's equity was 28.33 B KRW, a 59.69% increase from the 17.74 B KRW equity in the previous year.

The MFC Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2022
-1.96 B KRW
Jan 1, 2023
17.74 B KRW
Jan 1, 2024
28.33 B KRW
The MFC Co Equity history
YEAREquityYoY
28.33 BKRW+59.69%
17.74 BKRW-1,006.04%
-1.96 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MFC Co Stock analysis

What does MFC Co do? MFC Co Ltd generates revenue primarily through the development and production of active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials for the pharmaceutical industry. The company focuses on creating basic pharmaceutical substances and raw material pharmaceuticals, serving clients in the pharmaceutical sector. Its products are sold to pharmaceutical manufacturers who require these materials for drug formulation. The company operates within the pharmaceutical research and development segment, targeting firms involved in drug production and formulation. MFC Co Ltd's business model centers on providing essential raw materials and intermediates to pharmaceutical companies. By specializing in API, KSM, and intermediate materials, the company supports the manufacturing processes of its clients. The firm's revenue streams are derived from the sale of these specialized pharmaceutical components to manufacturers who integrate them into their final drug products. The company's target market consists of pharmaceutical manufacturers requiring high-quality raw materials for their production lines. The company's core offerings include active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials, which are critical for pharmaceutical manufacturing. These products are sold to pharmaceutical manufacturers as part of their supply chain. MFC Co Ltd's revenue is generated through the direct sale of these materials to clients in the pharmaceutical industry. The company's focus on R&D for pharmaceutical substances ensures a steady demand for its products from drug manufacturers seeking reliable suppliers. MFC Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing MFC Co's Equity

MFC Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding MFC Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating MFC Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

MFC Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in MFC Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about MFC Co stock

The Equity of MFC Co is 28.33 B KRW in 2024.

The Equity of MFC Co changed from 17.74 B KRW to 28.33 B KRW, representing a 59.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity MFC Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's MFC Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — MFC Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — MFC Co